| Neuroinflammation in Alzheimer's disease MT Heneka, MJ Carson, J El Khoury, GE Landreth, F Brosseron, ... The Lancet Neurology 14 (4), 388-405, 2015 | 5972 | 2015 |
| NLRP3 is activated in Alzheimer’s disease and contributes to pathology in APP/PS1 mice MT Heneka, MP Kummer, A Stutz, A Delekate, S Schwartz, ... Nature 493 (7434), 674-678, 2013 | 2834 | 2013 |
| Innate immune activation in neurodegenerative disease MT Heneka, MP Kummer, E Latz Nature Reviews Immunology 14 (7), 463-477, 2014 | 1582 | 2014 |
| New insights into the genetic etiology of Alzheimer’s disease and related dementias C Bellenguez, F Küçükali, IE Jansen, L Kleineidam, S Moreno-Grau, ... Nature genetics 54 (4), 412-436, 2022 | 1562 | 2022 |
| NLRP3 inflammasome activation drives tau pathology C Ising, C Venegas, S Zhang, H Scheiblich, SV Schmidt, A Vieira-Saecker, ... Nature 575 (7784), 669-673, 2019 | 1160 | 2019 |
| Microglia states and nomenclature: A field at its crossroads RC Paolicelli, A Sierra, B Stevens, ME Tremblay, A Aguzzi, B Ajami, I Amit, ... Neuron 110 (21), 3458-3483, 2022 | 1071 | 2022 |
| Inflammatory processes in Alzheimer's disease MT Heneka, MK O'Banion Journal of neuroimmunology 184 (1-2), 69-91, 2007 | 993 | 2007 |
| Microglia-derived ASC specks cross-seed amyloid-β in Alzheimer’s disease C Venegas, S Kumar, BS Franklin, T Dierkes, R Brinkschulte, D Tejera, ... Nature 552 (7685), 355-361, 2017 | 918 | 2017 |
| Innate immunity in Alzheimer's disease MT Heneka, DT Golenbock, E Latz Nature immunology 16 (3), 229-236, 2015 | 867 | 2015 |
| Microglia in Alzheimer’s disease H Sarlus, MT Heneka The Journal of clinical investigation 127 (9), 3240-3249, 2017 | 856 | 2017 |
| TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis G Kleinberger, Y Yamanishi, M Suárez-Calvet, E Czirr, E Lohmann, ... Science translational medicine 6 (243), 243ra86-243ra86, 2014 | 818 | 2014 |
| A guiding map for inflammation MG Netea, F Balkwill, M Chonchol, F Cominelli, MY Donath, ... Nature immunology 18 (8), 826-831, 2017 | 798 | 2017 |
| Acute treatment with the PPARγ agonist pioglitazone and ibuprofen reduces glial inflammation and Aβ1–42 levels in APPV717I transgenic mice MT Heneka, M Sastre, L Dumitrescu-Ozimek, A Hanke, I Dewachter, ... Brain 128 (6), 1442-1453, 2005 | 744 | 2005 |
| Inflammasome signalling in brain function and neurodegenerative disease MT Heneka, RM McManus, E Latz Nature Reviews Neuroscience 19 (10), 610-621, 2018 | 699 | 2018 |
| Glial cells in (patho) physiology V Parpura, MT Heneka, V Montana, SHR Oliet, A Schousboe, PG Haydon, ... Journal of neurochemistry 121 (1), 4-27, 2012 | 693 | 2012 |
| Immediate and long-term consequences of COVID-19 infections for the development of neurological disease MT Heneka, D Golenbock, E Latz, D Morgan, R Brown Alzheimer's research & therapy 12, 1-3, 2020 | 640 | 2020 |
| Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine MT Heneka, F Nadrigny, T Regen, A Martinez-Hernandez, ... Proceedings of the National Academy of Sciences 107 (13), 6058-6063, 2010 | 584 | 2010 |
| Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists C Grommes, GE Landreth, MT Heneka The lancet oncology 5 (7), 419-429, 2004 | 581 | 2004 |
| Contribution of inflammatory processes to Alzheimer's disease: molecular mechanisms M Sastre, T Klockgether, MT Heneka International Journal of Developmental Neuroscience 24 (2-3), 167-176, 2006 | 559 | 2006 |
| Neuroinflammatory processes in Alzheimer’s disease MT Heneka, MK O’Banion, D Terwel, MP Kummer Journal of neural transmission 117, 919-947, 2010 | 542 | 2010 |